Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium

Asthma Clinical Trial

Official title:

A Biomarker-Based Pilot Study of Cockroach Subcutaneous Immunotherapy in Cockroach Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-18)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01221285
• Other study ID #: DAIT ICAC-18
• Secondary ID: SCITCO
• Status: Completed
• Phase: Phase 1
• First received: October 13, 2010
• Last updated: June 5, 2014
• Start date: September 2010
• Est. completion date: October 2011

Study information

• Verified date: June 2014
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

This trial is a biomarker-based pilot study of the safety of Cockroach Subcutaneous Immunotherapy in Cockroach-sensitive Adults (SCITCO) who have a history of perennial allergic rhinitis, asthma, or both.

Description:

Scientific evidence has shown that, over the past two decades, the combination of cockroach allergy and cockroach exposure is one of the most important factors contributing to the dramatic increase in asthma morbidity seen in inner city children with asthma. Therefore, a major goal of the Inner City Asthma Consortium (ICAC) is to evaluate the efficacy of cockroach immunotherapy in inner city asthma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: October 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Have a history of perennial allergic rhinitis, asthma, or both, for a minimum of 1 year before study entry. For those with asthma:

• a diagnosis of asthma will be defined as a report by the participant that they have had a clinical diagnosis of asthma made by a physician over a year ago

• the participant's asthma must be well controlled as defined by:

• a forced expiratory volume at one second (FEV1) greater than or equal to 80% predicted value with or without controller medication

• albuterol use for no more than 3 days per week in each of the previous 2 weeks for asthma symptoms (not including exercise prophylaxis)

• Are sensitive to German cockroach (Blattella germanica) as documented by a positive (>= 3 mm greater than negative control) skin prick test result and detectable German cockroach specific IgE (>=0.35 kUA/L)

• Have no known contraindications to therapy with glycerinated German (Blattella germanica) cockroach allergenic extract

• Are willing to sign the written Informed Consent prior to initiation of any study procedure

Exclusion Criteria:

• Are pregnant or lactating. Females must be abstinent or use a medically acceptable birth control method throughout the study (e.g. oral, subcutaneous, mechanical, or surgical contraception)

• Are unable to perform spirometry at screening

• Have an asthma severity classification at recruitment of severe persistent, using the National Asthma Education and Prevention Program (NAEPP) classification, as evidenced by at least one of the following:

• requires a dose of greater than 500 mcg of fluticasone per day or the equivalent of another inhaled corticosteroid

• have received more than 2 courses of oral or parenteral corticosteroids within the last 12 months

• have been treated with depot steroids within the last 12 months

• have been hospitalized for asthma within the 6 months prior to recruitment

• have had a life-threatening asthma exacerbation that required intubation, mechanical ventilation, or that resulted in a hypoxic seizure within 2 years prior to recruitment

• Do not have access to a phone (needed for scheduling appointments)

• Have received allergen immunotherapy (SLIT or SCIT) in the last 12 months prior to recruitment or who plan to initiate or resume allergen immunotherapy during the study. Subjects who only received placebo therapy in the BioCSI protocol (A Biomarker-based Pilot Study of Cockroach Sublingual Immunotherapy in Cockroach Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis, ICAC-12, NCT00829985) are eligible to participate in this study

• Have previously been treated with anti-IgE therapy within 1 year of recruitment

• Have received an investigational drug in the 30 days prior to recruitment or who plan to use an investigational drug during the study

• Refuse to sign the Epinephrine Auto-injector Training Form

• Do not primarily speak English

• Plan to move from the area during the study period

• Have a history of idiopathic anaphylaxis or anaphylaxis grade 2 or higher as defined in the protocol

• Have unstable angina, significant arrhythmia, uncontrolled hypertension, history of autoimmune disease, or other chronic or immunological diseases that in the opinion of the investigator might interfere with the evaluation of the investigational agent or pose additional risk to the participant

• Are using tricyclic antidepressants or beta-adrenergic blocker drugs (either oral or topical route[s] of administration)

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Asthma
• Perennial Allergic Rhinitis
• Rhinitis
• Rhinitis, Allergic, Perennial

Intervention

Biological:
• German cockroach (Blattella germanica) allergenic extract
Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.

Locations

Country	Name	City	State
United States	Johns Hopkins University School of Medicine	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Inner-City Asthma Consortium

Country where clinical trial is conducted

United States, 

References & Publications (1)

Wood RA, Togias A, Wildfire J, Visness CM, Matsui EC, Gruchalla R, Hershey G, Liu AH, O'Connor GT, Pongracic JA, Zoratti E, Little F, Granada M, Kennedy S, Durham SR, Shamji MH, Busse WW. Development of cockroach immunotherapy by the Inner-City Asthma Con — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Reported Treatment-related Adverse Events (AEs)	Number of non-serious adverse events reported as possibly related, probably related, or definitely related to study participation.	Baseline through 6-months of treatment	Yes
Primary	Number of Reported Treatment-related Serious Adverse Events (SAEs)	Number of SAEs reported as possibly related, probably related, or definitely related to study participation.	Baseline through 6-months of treatment	Yes
Secondary	Change in German Cockroach-Specific Serum IgE Over Time	Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin E (IgE) vs. post-baseline German cockroach-specific serum IgE. Numerator is geometric mean post-baseline IgE; denominator is baseline IgE. This result is an indicator of immune modulation over time, however its clinical significance is unclear.	Baseline through 6-months of treatment	No
Secondary	Change in German Cockroach-Specific Serum IgG Over Time	Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin G (IgG) vs. post-baseline German cockroach-specific serum IgG. Numerator is geometric mean post-baseline IgG; denominator is baseline IgG.This result is an indicator of immune modulation over time, however its clinical significance is unclear.	Baseline through 6-months of treatment	No
Secondary	Change in German Cockroach-Specific Serum IgG4 Over Time	Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin subclass 4 (IgG4) vs. post-baseline German cockroach-specific serum IgG4. Numerator is geometric mean post-baseline IgG4; denominator is baseline IgG4. This result is an indicator of immune modulation over time, however its clinical significance is unclear.	Baseline through 6-months of treatment	No
Secondary	Change in IgE Fragment Antibody Binding (FAB) Activity (10 Micrograms/mL Cockroach Allergen Extract)	Outcome is the change in mean IgE fragment antibody binding (FAB) activity, baseline to post-baseline. Serum from cockroach subcutaneous immunotherapy (SCIT)-treated participants were analyzed to determine if treatment inhibits the in-vitro cockroach antigen binding to B-cells after 6-months of treatment with cockroach SCIT, using the per protocol allergenic extract doses. This result is an indicator of immune modulation over time, however its clinical significance is unclear.	Baseline through 6-months of treatment	No